This clinical trial is a non-interventional, observational, multicenter, post-marketing real-world study to evaluate the efficacy and safety of Inaticabtagene Autoleucel Injection in Chinese adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Age ≥ 18 years;
Diagnosed with relapsed or refractory B-cell acute lymphoblastic leukemia;
Patients deemed eligible for receiving commercial Inaticabtagene Autoleucel injection treatment as determined by the investigator;
Patients voluntarily participate in this study and sign an informed consent form. For patients lacking full legal capacity, informed consent must be obtained from their legal guardian
None
Diagnosed with adult relapsed or refractory B-cell acute lymphoblastic leukemia.
Cohort
Prospective
Not listed
overall survival
OS is defined as the time from the start date of Inaticabtagene Autoleucel Injection infusion to the date of death due to any cause.
Click on the lead sponsor to view all of their trials.
